Nelkarmi FDA Approval: Neladalkib Wins Accelerated Nod for Previously Treated ALK-Positive Lung Cancer

The U.S. Food and Drug Administration on November 17, 2026, granted accelerated approval to Nelkarmi (neladalkib), a new targeted pill for adults with ALK-positive lung cancer whose disease has already been treated with earlier ALK inhibitors. The Nelkarmi FDA approval gives patients with ALK-positive non-small cell lung cancer (NSCLC) a new option after resistance develops — a point in treatment where choices have historically been limited. The drug was developed by Nuvalent, now part of GSK.
Below, we explain what the drug does, what the trial data show, the safety picture, and what still has to be proven. We label verified regulatory facts, company statements, and expert commentary separately.
Nelkarmi FDA Approval at a Glance
| Item | Detail |
|---|---|
| Drug | Nelkarmi (neladalkib), an oral ALK-selective kinase inhibitor |
| Company | Nuvalent, Inc., a GSK company (GSK: NYSE/LSE) |
| Decision | Accelerated approval, November 17, 2026 — ahead of the November 27 target action date, per GSK |
| Who it’s for | Adults with locally advanced or metastatic ALK-positive NSCLC previously treated with alectinib, or with two or more prior ALK inhibitors plus platinum chemotherapy |
| Dose | 150 mg by mouth once daily, with or without food |
| Pivotal study | ALKOVE-1 (NCT05384626), single-arm phase 1/2 |
| FDA designations | Priority review, breakthrough therapy, orphan drug |
The Science in Plain Language
In a small share of lung cancers, a gene called ALK becomes fused with another gene. The resulting fusion protein acts like a stuck “on” switch that drives tumor growth. ALK-positive NSCLC tends to affect younger people and people who have never smoked, and it often spreads to the brain.
Several ALK inhibitors already exist, and many patients respond well at first. Over time, though, tumors often develop new ALK mutations that make earlier drugs less effective, or the cancer progresses in the brain. According to its developer, neladalkib was designed to address those problems:
- Built for resistance: it is engineered to remain active against ALK mutations that cause resistance to earlier drugs, including compound mutations.
- Brain-penetrant: it is designed to cross into the central nervous system, where ALK-positive cancer commonly spreads.
- ALK-selective: it aims to avoid a related protein, TRK, whose inhibition is linked to neurological side effects such as dizziness and weight gain seen with some earlier drugs.
The Evidence So Far: ALKOVE-1 Results
Verified facts (FDA)
According to the FDA’s approval announcement, efficacy was measured in ALKOVE-1, a multicenter, single-arm, open-label, multi-cohort trial. The main measure was the confirmed objective response rate (ORR) — the share of patients whose tumors shrank meaningfully — judged by blinded independent central review.
| Patient group | Patients | Response rate (95% CI) | Responders lasting ≥6 months | Responders lasting ≥12 months |
|---|---|---|---|---|
| Previously treated with alectinib (one prior ALK inhibitor) | 67 | 49% (37%–62%) | 76% | 52% |
| Two or more prior ALK inhibitors plus platinum chemotherapy | 155 | 32% (24%–40%) | 69% | 51% |
Source: FDA, November 17, 2026.
Company-reported data (GSK)
In its approval announcement, GSK also reported intracranial (brain) responses among patients who had measurable brain metastases at the start of the study:
- Alectinib-pretreated group: intracranial response rate of 55% (11 of 20 patients), including 25% complete responses.
- Two or more prior ALK inhibitors plus chemotherapy: intracranial response rate of 26% (14 of 53 patients), including 11% complete responses.
The FDA announcement itself did not report intracranial response rates, progression-free survival, or overall survival.
How strong is this evidence?
Analysis: Accelerated approval allows the FDA to clear a drug based on an early measure, such as tumor shrinkage, that is reasonably likely to predict real clinical benefit. Because ALKOVE-1 had no comparison group, its response rates cannot be directly compared with results for other ALK inhibitors, and the trial does not show whether patients live longer. Under the accelerated approval pathway, continued approval generally depends on further studies confirming clinical benefit.
Safety Profile
The FDA lists warnings and precautions for:
- Hepatotoxicity (liver injury)
- Renal (kidney) toxicity
- Ocular (eye) toxicity
- Creatine phosphokinase (CPK) elevation, a sign of muscle injury
- Embryo-fetal toxicity
The most common side effects, occurring in at least 20% of patients, were liver toxicity, musculoskeletal pain, constipation, altered taste (dysgeusia), peripheral neuropathy, swelling (edema), and fatigue. GSK reported that 5% of patients permanently stopped treatment because of side effects, most often liver toxicity.
Who Could Benefit
The approval covers adults whose ALK-positive NSCLC is advanced or metastatic and cannot be removed with surgery, and who have already received either alectinib — a widely used first-line ALK inhibitor — or at least two ALK inhibitors plus platinum-based chemotherapy. Patients should talk with their oncologist about whether the drug fits their situation.
What People Are Saying
Company statement
Tony Wood, Chief Scientific Officer at GSK, said: “Nelkarmi is our second new medicine approved in lung cancer this year.” GSK’s first, Jideytro (zidesamtinib) for previously treated ROS1-positive NSCLC, was approved in July after GSK’s $10.6 billion acquisition of Nuvalent.
Expert commentary
Dr. Alice Shaw, an ALKOVE-1 investigator and Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, said in the GSK release: “The approval of neladalkib provides an important new treatment option for patients.”
Next Steps
- Confirmatory evidence: Neladalkib is being tested in ALKAZAR (NCT06765109), an ongoing phase 3 trial comparing it with alectinib in patients who have not previously received an ALK inhibitor. GSK did not give a timeline for results.
- Ongoing study: ALKOVE-1 continues to enroll patients.
- Prescribing information: Full labeling is to be posted on Drugs@FDA. GSK did not announce launch timing or pricing.
Related Coverage on Vanderbiltreport.com
- Petosemtamab Phase 3 Results: Genmab Head and Neck Cancer Drug Cuts Death Risk 50% With Keytruda
- FDA Approves Hibsago: A New Chronic Hepatitis B Treatment Aims for a “Functional Cure”
- Huntington’s Disease Gene Therapy AMT-130 Gets FDA Priority Review
- Hepatitis Delta Phase 3 Results: Vir’s Elebsiran and Tobevibart Meet Primary Goal in ECLIPSE 1
Sources
- FDA: FDA grants accelerated approval to neladalkib (November 17, 2026)
- GSK press release: Nelkarmi (neladalkib) approved in the US (November 17, 2026)
- AJMC: FDA Grants Accelerated Approval to Neladalkib
- ClinicalTrials.gov: ALKOVE-1 (NCT05384626)
- ClinicalTrials.gov: ALKAZAR (NCT06765109)
- GSK: GSK completes acquisition of Nuvalent, Inc.
This article is for informational purposes only and is not medical advice. Patients should consult their healthcare providers about treatment decisions.
Publisher Disclaimer: Vanderbiltreport.com publishes news and information for general informational and educational purposes. Information is compiled from sources believed to be reliable, but Vanderbiltreport.com does not guarantee the accuracy, completeness, or timeliness of all information presented. Readers should independently verify information and conduct their own research before making financial, investment, business, or other decisions.
